2021 Pipeline Insights on NK Cell Therapy - Featuring Nantkwest, Coronado Biosciences and Affimed Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "NK Cell Therapy - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in NK cell therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

NK cell therapy Emerging Drugs Chapters

This segment of the NK cell therapy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NK cell therapy Emerging Drugs

haNK + avelumab + IL-15 Fusion Protein Combination Therapy: Nantkwest

NantKwest is developing an off-the-shelf natural killer cell-based therapeutic in combination with N-803 and ImmunityBio's IL-15 superagonist for the treatment of advanced refractory metastatic merkel cell carcinoma. The therapy leverages the company's hANK Cell Platform. The drug is in Phase II of clinical development.

NK cell therapy: Therapeutic Assessment

This segment of the report provides insights about the different NK cell therapy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on NK cell therapy

There are approx. 15+ key companies which are developing the NK cell therapy. The companies which have their NK cell therapy drug candidates in the most advanced stage, i.e. phase II include, Nantkwest.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I/II and Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

NK cell therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NK cell therapy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses NK cell therapy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NK cell therapy drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NK cell therapy R&D. The therapies under development are focused on novel approaches for NK cell therapy.

• A global increase in Cancer incident cases and relapses has led to an inclination towards Novel effective treatments such as adjuvant therapy drugs, and NK cell therapies.

NK cell therapy Report Insights

• NK cell therapy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

NK cell therapy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

• How many companies are developing NK cell therapy drugs?
• How many NK cell therapy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for NK cell therapy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the NK cell therapy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for NK cell therapy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Nantkwest
• Coronado Biosciences
• Artiva Biotherapeutics
• Affimed
• Bristol-Myers Squibb
• Celularity Incorporated
• ZIOPHARM Oncology
• Surface Oncology
• Sorrento Therapeutics
• AvidBiotic Corporation

Key Products

• Avelumab; N-803; hank
• AB-101
• CNDO-109-AANK Cells
• NK cells combined with the antibody AFM13 (AFM13-NK) and AFM13 alone
• Lirilumab; Nivolumab; Ipilimumab
• CYNK-001

Companies Mentioned

• Nantkwest
• Coronado Biosciences
• Artiva Biotherapeutics
• Affimed
• Bristol-Myers Squibb
• Celularity Incorporated
• ZIOPHARM Oncology
• Surface Oncology
• Sorrento Therapeutics
• AvidBiotic Corporation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/atw6mn